The CA10 antibody targets carbonic anhydrase-related protein X (CA10), a member of the carbonic anhydrase (CA) family. Unlike enzymatically active CAs, CA10 lacks catalytic activity due to mutations in its active site. It is primarily expressed in the central nervous system, particularly in the cerebellum, and plays roles in neuronal development and synaptic signaling. CA10 is implicated in neurodevelopmental disorders, such as autism spectrum disorders, and has been linked to tumorigenesis in certain cancers, including renal cell carcinoma and gliomas. Its overexpression in tumors suggests potential as a diagnostic or prognostic biomarker. CA10 antibodies are essential tools for detecting protein expression in tissues via immunohistochemistry (IHC), Western blotting, or immunofluorescence. Research utilizing these antibodies aims to elucidate CA10's biological functions, its interaction with neural pathways like the MET tyrosine kinase receptor, and its role in disease mechanisms. Commercial CA10 antibodies are typically developed in rabbits or mice, with validation in specific experimental models. Ongoing studies explore its therapeutic potential and regulatory mechanisms in both neurological and oncological contexts.